HDAC inhibitors and other histone modifying natural products as emerging anticancer agents

Natural Products and Cancer Drug Discovery

Volumn , Issue , 2013, Pages 59-95

  Salvador, Lilibeth A ^a   Luesch, Hendrik ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84937413327     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4654-5_4     Document Type: Chapter

References (185)

1. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rikfin DB (1994) An assay for transforming growth factor-beta using cells transfected with plasminogen activator inhibitor-1 promoterluciferase construct. Anal Biochem 216:276-284.
2. Altman SA, Randers L, Rao G (1999) Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations. Biotechnol Prog 9:871-874.
3. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22:7468-7485.
4. Anand R, Marmorstein R (2007) Structure and mechanism of lysine-specific demethylase enzymes. J Biol Chem 282:35425-35429.
5. Aoyagi S, Archer TK (2005) Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol 15:565-567.
6. Arif M, Pradhan SK, Thanuja GK et al (2009) Mechanism of p300 specific histone acetyltransferase inhibition by small molecules. J Med Chem 52:267-277.
7. Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ (2008) A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22:1026-1034.
8. Balasubramanyam K, Altaf M, Varier RA et al (2004) Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 279:33716-33726.
9. Balcerczyk A, Pirola L (2010) Therapeutic potential of activators and inhibitors of sirtuins. Biofactors 36:383-393.
10. Barlev NA, Liu L, Chehab NH et al (2001) Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 8:1243-1254.
11. Bartz SR, Zhang Z, Burchard J et al (2006) Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 26:9377-9386.
12. Baur JA, Pearson KJ, Price NL et al (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337-342.
13. Beher D, Wu J, Cumine S et al (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74:619-624.
14. Berndsen CE, Albaugh BN, Tan S, Denu JM (2007) Catalytic mechanism of a MYST family histone acetyltransferase. Biochemistry 46:623-629.
15. Bolden J, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784.
16. Borra MT, Smith BC, Denu JM (2005) Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280:17187-17195.
17. Bottomley MJ, Lo Surdo P, Di Giovine P et al (2008) Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem 283:26694-26704.
18. Bowers AA, Greshock TJ, West N et al (2009) Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole. J Am Chem Soc 131:2900-2905.
19. Breslow R, Jursic B, Yan ZF et al (1991) Potent cytodifferentiating agents related to hexamethylenebisacetamide. Proc Natl Acad Sci U S A 88:5542-5546.
20. Bressi JC, Jennings AJ, Skene R et al (2010) Exploration of the HDAC2 foot pocket: synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett 20:3142-3145.
21. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107.
22. Chen Y, Gambs C, Abe Y, Wentworth PJ, Janda KD (2003) Total synthesis of the depsipeptide FR-901375. J Org Chem 68:8902-8905.
23. Chen L, Williams SA, Mu Y et al (2005) NF-CB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 25:7966-7975.
24. Cheng X, Blumenthal RM (2008) Mammalian DNA methyltransferases: a structural perspective. Structure 16:341-350.
25. Choudhary C, Kumar C, Gnad F et al (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325:834-843.
26. Clark GJ, Cox A, Graham SM, Der CJ (1995) Biological assays for Ras transformation. In: Balch WE, Der CJ, Hall A (eds) Methods in enzymology. Academic, New York.
27. Closse A, Huguenin R (1974) Isolierung und Strukturaufklärung von Chlamydocin. Helv Chim Acta 57:533-544.
28. Cole KE, Dowling DP, Boone MA, Phillips AJ, Christianson DW (2011) Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J Am Chem Soc 133:12474-12477.
29. Culhane JC, Cole PA (2007) LSD1 and the chemistry of histone demethylation. Curr Opin Chem Biol 11:561-568.
30. Dal Piaz F, Tosco A, Eletto D et al (2010) The identification of a novel natural activator of p300 histone acetyltransferase provides new insights into the modulation mechanism of this enzyme. ChemBioChem 11:818-827.
31. De Ruijter AJM, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg ABP (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737-749.
32. Dedesa KJ, Dedesa I, Imescha P, von Buerenb AO, Finka D, Fediera A (2009) Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anticancer Drugs 20:321-333.
33. Deng W, Wu KK (2003) Regulation of inducible nitric oxide synthase expression by p300 and p50 acetylation. J Immunol 171:6581-6588.
34. Deng W, Zhu Y, Wu KK (2003) Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-a-induced cyclooxygenase-2 promoter activation. J Biol Chem 278:4770-4777.
35. Di Lorenzo A, Bedford MT (2011) Histone arginine methylation. FEBS Lett 585:2024-2031.
36. Di Micco S, Terracciano S, Bruno I et al (2008) Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222. Bioorg Med Chem 16:8635-8642.
37. Dittenhafer-Reed KE, Feldman JL, Denu JM (2011) Catalysis and mechanistic insights into sirtuin activation. ChemBioChem 12:281-289.
38. Elaut G, Torok G, Vinken M et al (2002) Major phase I biotransformation pathways of trichostatin A in rat hepatocytes and in rat and human liver microsomes. Drug Metab Dispos 30:1320-1328.
39. Fantin VR, Loboda A, Paweletz CP et al (2008) Constitutive activation of signal transducers and activators of transcription predicts Vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 68:3785-3794.
40. Fedier A, Dedes KJ, Imesch P, Von Bueren AO, Fink D (2007) The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int J Oncol 31:633-641.
41. Ficner R (2009) Novel structural insights into Class I and II histone deacetylases. Curr Top Med Chem 9:235-240.
42. Finnin MS, Donigian JR, Cohen A et al (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-193.
43. Frew AJ, Lindemann RK, Martin BP et al (2008) Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A 105:11317-11322.
44. Fry DG, Hurlin PJ, Maher VM, McCormick JJ (1988) Transformation of diploid human fibroblasts by transfection with the v-sis, PDGF2/c-sis, or T24 H-ras genes. Mutat Res 199:341-351.
45. Furumai R, Matsuyama A, Kobashi N et al (2002) FK228 (Depsipeptide) as a natural prodrug that inhibits Class I histone deacetylases. Cancer Res 62:4916-4921.
46. George P, Bali P, Annavarapu S et al (2005) Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105:1768-1776.
47. Gey C, Kyrylenko S, Hennig L et al (2007) Phloroglucinol derivatives guttiferone G, aristoforin, and hyperforin: inhibitors of human sirtuins SIRT1 and SIRT2. Angew Chem Int Ed 46:5219-5222.
48. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151-163.
49. Glozak MA, Sengupta N, Zhang X, Seto E (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15-23.
50. Gorre ME, Mohammed M, Ellwood K et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880.
51. Gregoretti IV, Lee Y, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338:17-31.
52. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A (2005) Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol 1:143-145.
53. Gu W, Cueto M, Jensen PR, Fenical W, Silverman RB (2007) Microsporins A and B: new histone deacetylase inhibitors from the marine-derived fungus Microsporum cf. gypseum and the solidphase synthesis of microsporin A. Tetrahedron 63:6535-6541.
54. Gutierrez M, Andrianasolo EH, Shin WK et al (2009) Structural and synthetic investigations of tanikolide dimer, a SIRT2 selective inhibitor, and tanikolide seco-acid from the Madagascar marine cyanobacterium Lyngbya majuscula. J Org Chem 74:5267-5275.
55. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL (2003) Domain-selective smallmolecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 100:4389-4394.
56. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59:177-189.
57. Hanigan CL, Van Engeland M, De Bruine AP et al (2008) An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. Gastroenterology 135:1654-1664.
58. Hauser D, Weber HP, Sigg HP (1970) Isolation and structure elucidation of chaetocin. Helv Chim Acta 53:1061-1073.
59. Hirota A, Suzuki A, Suzuki H, Tamura S (1973) Isolation and biological activity of Cyl-2, a metabolite of Cylindrocladium scoparium. Agric Biol Chem 37:643-647.
60. Hodawadekar SC, Marmorstein R (2007) Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 26:5528-5540.
61. Hong J, Luesch H (2012) Largazole: From discovery to broad-spectrum therapy. Nat Prod Rep 29: 449-456.
62. Hoshino I, Hisahiro M, Akutsu Y et al (2007) Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells. Oncol Rep 18:585-592.
63. Howitz KT, Bitterman KJ, Cohen HY et al (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191-196.
64. Hubbert C, Guardiola A, Shao R et al (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417:455-458.
65. Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM, Bible KC (2007) Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 109:2579-2588.
66. Itazaki H, Nagashima K, Sugita K et al (1990) Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J Antibiot 43:1524-1532.
67. Iwasa E, Hamashima Y, Fujishiro S et al (2010) Total synthesis of (+)-chaetocin and its analogues: their histone methyltransferase G9a inhibitory activity. J Am Chem Soc 132:4078-4079.
68. Jagadeesh S, Sinha S, Pal BC, Bhattacharya S, Banerjee PP (2007) Mahanine reverses an epigenetically silenced tumor suppressor gene RASSF1A in human prostate cancer cells. Biochem Biophys Res Commun 362:212-217.
69. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428.
70. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683-692.
71. Joubel A, Chalkley RJ, Medzihradszky KF, Hondermarck H, Burlingame AL (2009) Identification of new p53 acetylation sites in COS-1 cells. Mol Cell Proteomics 8:1167-1173.
72. Jurkowska RZ, Jurkowski TP, Jeltsch A (2011) Structure and function of mammalian DNA methyltransferases. ChemBioChem 12:206-222.
73. Kano Y, Akutsu M, Tsunoda S et al (2006) Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest New Drugs 25:31-40.
74. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao T (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727-738.
75. Kiernan R, Bres V, Ng RWM et al (2003) Post-activation turn-off of NF-KB-dependent transcription is regulated by acetylation of p65. J Biol Chem 278:2758-2766.
76. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T (1993) Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268:22429-22435.
77. Kim DH, Shin J, Kwon HJ (2007) Psammaplin A is a natural prodrug that inhibits class I histone deacetylase. Exp Mol Med 39:47-55.
78. Komatsu Y, Tomizaki K, Tsukamoto M et al (2001) Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res 61:4459-4466.
79. Kornberg RD, Lorch Y (1999) Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98:285-294.
80. Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693-705.
81. Kuck D, Caulfield T, Lyko F, Medina-Franco JL (2010) Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther 9:3015-3023.
82. Kwan JC, Luesch H (2010) Weapons in disguise-activating mechanisms and protecting group chemistry in Nature. Chem Eur J 16:13020-13029.
83. Kwon T, Chang JH, Kwak E et al (2003) Mechanism of histone lysine methyl transfer revealed by the structure of SET7/9-AdoMet. EMBO J 22:292-303.
84. Ledizet M, Piperno G (1987) Identification of an acetylation site of Chlamydomonas a-tubulin. Proc Natl Acad Sci U S A 84:5720-5724.
85. Lee WJ, Zhu BT (2006) Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 279:269-277.
86. Lee WJ, Shim J, Zhu BT (2005) Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol 68:1018-1030.
87. Lee J, Smith E, Shilatifard A (2010) The language of histone crosstalk. Cell 142:682-685.
88. Li B, Carey M, Workman JL (2007) The role of chromatin during transcription. Cell 128:707-719.
89. Liang G, Lin JCY, Wei V et al (2004) Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci U S A 101:7357-7362.
90. Lin Y, Fletcher CM, Zhou J, Allis CD, Wagner G (1999) Solution structure of the catalytic domain of GCN5 histone acetyltransferase bound to coenzyme A. Nature 400:86-89.
91. Lina R, Hsu C, Wang Y (2007) Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells. Anticancer Drugs 18:1157-1164.
92. Liu X, Wang L, Zhao K et al (2008) The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451:846-850.
93. Liu Z, Liu S, Xie Z et al (2009) Modulation of DNA methylation by a sesquiterpene lactone parthenolide. J Pharmacol Exp Ther 329:505-514.
94. Liu Y, Salvador LA, Byeon S et al (2010) Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor. J Pharmacol Exp Ther 335:351-361.
95. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ (1997) Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 389:251-260.
96. Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84-90.
97. Maruta H, Greet K, Rosenbaum JL (1986) The acetylation of alpha-tubulin and its relationship to the assembly and disassembly of microtubules. J Cell Biol 103:571-579.
98. Masuoka Y, Nagai A, Shin-ya K et al (2001) Spiruchostatins A and B, novel gene expressionenhancing substances produced by Pseudomonas sp. Tetrahedron Lett 42:41-44.
99. Masuoka Y, Shindoh N, Inamura N (2008) Histone deacetylase inhibitors from microorganisms: the Astellas experience. In: Amstutz R, Petersen F (eds) Progress in drug research. Birkhauser Verlag, Basel.
100. Maulucci N, Chini MG, Di Micco S et al (2007) Molecular insights into azumamide E histone deacetylases inhibitory activity. J Am Chem Soc 129:3007-3012.
101. McCulloch MWB, Coombs GS, Banerjee N et al (2009) Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives. Bioorg Med Chem 17:2189-2198.
102. McPhail KL, France D, Cornell-Kennon S, Gerwick WH (2004) Peyssonenynes A and B, novel enediyne oxylipins with DNA methyltransferase inhibitory activity from the red marine alga Peyssonnelia caulifera. J Nat Prod 67:1010-1013.
103. Min J, Feng Q, Li Z, Zhang Y, Xu R (2003) Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell 112:711-723.
104. Mori H, Urano Y, Abe F et al (2003a) FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC). I. Taxonomy, fermentation, isolation and biological activities. J Antibiot 56:72-79.
105. Mori H, Abe F, Furukawa S et al (2003b) FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC). II. Biological activities in animal models. J Antibiot 56:80-86.
106. Mori H, Urano Y, Kinoshita T, Yoshimura S, Takase S, Hino M (2003c) FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase. III. Structure determination. J Antibiot 56:181-185.
107. Mosammaparast N, Shi Y (2010) Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem 79:155-179.
108. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
109. Nakagawa M, Oda Y, Eguchi T et al (2007) Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18:769-774.
110. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241:126-133.
111. Nakao Y, Yoshida S, Matsunaga S et al (2006) Azumamides A-E: histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale izuensis. Angew Chem Int Ed 45:7553-7557.
112. Nawrocki ST, Carew JS, Pino MS et al (2006) Aggresome disruption: a novel strategy to enhance Bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 66:3773-3781.
113. Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat Prod 75:311-335.
114. Nie L, Ueki M, Kakeya H, Osada H (2001) A facile and effective screening method for p21WAF1 promoter activators from microbial metabolites. J Antibiot 54:783-788.
115. Noh JH, Song JH, Eun JW et al (2009) Systemic cell-cycle suppression by apicidin, a histone deacetylase inhibitor, in MDA-MB-435 cells. Int J Mol Med 24:205-226.
116. O'Brien J, Wilson I, Orton T, Pognan F (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267:5421-5426.
117. Oh WK, Cho KB, Hien TT et al (2010) Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance. Mol Pharmacol 78:855-864.
118. Oliver SS, Denu JM (2011) Dynamic interplay between histone H3 modifications and protein interpreters: emerging evidence for a "histone language". ChemBioChem 12:299-307.
119. Pacholec M, Bleasdale JE, Chrunyk B et al (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285:8340-8345.
120. Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH (1997) Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 208:151-158.
121. Pina IC, Gautschi JT, Wang G et al (2003) Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem 68:3866-3873.
122. Piperno G, LeDizet M, Chang X (1987) Microtubules containing acetylated a-tubulin in mammalian cells in culture. J Cell Biol 104:289-302.
123. Quivy V, Van Lint C (2004) Regulation at multiple levels of NF-QB-mediated transactivation by protein acetylation. Biochem Pharmacol 68:1221-1229.
124. Rahmani M, Yu C, Dai Y et al (2003) Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 63:8420-8427.
125. Reuben RC, Wife RL, Breslow R, Rifkind RA, Marks PA (1976) A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc Natl Acad Sci U S A 73:862-866.
126. Richon VM, Webb Y, Merger R et al (1996) Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A 93:5705-5708.
127. Richon VM, Garcia-Vargas J, Hardwick JS (2009) Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280:201-210.
128. Rodriguez-Gonzalez A, Lin T, Ikeda AK, Simms-Waldrip T, Fu C, Sakamoto KM (2008) Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res 68:2557-2560.
129. Ropero S, Fraga MF, Ballestar E et al (2006) A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 38:566-569.
130. Ropero S, Ballestar E, Alaminos M, Arango D, Schwartz S Jr, Esteller M (2008) Transforming pathways unleashed by a HDAC2 mutation in human cancer. Oncogene 27:4008-4012.
131. Sanders BD, Jackson B, Marmorstein R (2010) Structural basis for sirtuin function: what we know and what we don't. Biochim Biophys Acta 1804:1604-1616.
132. Sanderson L, Taylor GW, Aboagye EO et al (2004) Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin A after intraperitoneal administration to mice. Drug Metab Dispos 32:1132-1138.
133. Schuetz A, Min J, Allali-Hassani A et al (2008) Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem 283:11355-11363.
134. Scroggins BT, Robzyk K, Wang D et al (2007) An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 25:151-159.
135. Shah MH, Binkley P, Chan K et al (2006) Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 12:3997-4003.
136. Shao W, Growney JD, Feng Y et al (2010) Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance. Int J Cancer 127:2199-2208.
137. Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31:27-36.
138. Shigematsu N, Ueda H, Takase S, Tanaka H (1994) FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J Antibiot 47:311-314.
139. Shimada J, Kwon HJ, Sawamura M, Schreiber S (1995) Synthesis and cellular characterization of the detransformation agent, (-)-depudecin. Chem Biol 2:517-525.
140. Singh SB, Zink DL, Polishook JD et al (1996) Apicidins: novel cyclic tetrapeptides as coccidiostats and antimalarial agents from Fusarium pallidoroseum. Tetrahedron Lett 37:8077-8080.
141. Singh SB, Zink DL, Liesch JM et al (2001) Structure, histone deacetylase, and antiprotozoal activities of apicidins B and C, congeners of apicidin with proline and valine substitutions. Org Lett 3:2815-2818.
142. Sippl W, Jung M (2009) DNA methyltransferase inhibitors. Methods Princ Med Chem 42:163-183.
143. Smith BC, Denu JM (2009) Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta 1789:45-57.
144. Somoza JR, Skene RJ, Katz BA et al (2004) Structural snapshots of human HDAC8 provide insights into the Class I histone deacetylases. Structure 12:1325-1334.
145. Song J, Noh JH, Lee JH et al (2005) Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113:264-268.
146. Spannhoff A, Hauser A, Heinke R, Sippl W, Jung M (2009) The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem 42:1568-1582.
147. Stähelin H, Trippmacher A (1974) Cytostatic activity of chlamydocin, a rapidly inactivated cyclic tetrapeptide. Eur J Cancer 103:801-808.
148. Strober W (2001) Trypan blue exclusion test of cell viability. Curr Protoc Immunol Appendix 3:A.3B.1-A.3B.2.
149. Tanaka M, Levy J, Terada M, Breslow R, Rifkind RA, Marks PA (1975) Induction of erythroid differentiation in murine virus infected erythroleukemia cells by highly polar compounds. Proc Natl Acad Sci U S A 72:1003-1006.
150. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W (2008) Acetylation is indispensable for p53 activation. Cell 133:612-626.
151. Tanner KG, Trievel RC, Kuoi M et al (1999) Catalytic mechanism and function of invariant glutamic acid 173 from the histone acetyltransferase GCN5 transcriptional coactivator. J Biol Chem 274:18157-18160.
152. Taori K, Paul VJ, Luesch H (2008) Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc 130:1806-1807.
153. Taunton J, Collins JL, Schreiber SL (1996a) Synthesis of natural and modified trapoxins, useful reagents for exploring histone deacetylase function. J Am Chem Soc 118:10412-10422.
154. Taunton J, Hassig CA, Schreiber SL (1996b) A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272:408-411.
155. Teng Y, Iuchi K, Iwasa E et al (2010) Unnatural enantiomer of chaetocin shows strong apoptosis-inducing activity through caspase-8/caspase-3 activation. Bioorg Med Chem Lett 20:5085-5088.
156. Tessier P, Smil DV, Wahhab A et al (2009) Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett 19:5684-5688.
157. Thaler F, Minucci S (2011) Next generation histone deacetylase inhibitors: the answer to the search for optimized epigenetic therapies? Expert Opin Drug Discov 6:393-404.
158. Tibodeau JD, Benson LM, Isham CR, Owen WG, Bible KC (2009) The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase. Antioxid Redox Signal 11:1097-1106.
159. Ueda H, Nakajima H, Hori Y et al (1994a) FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot 47:301-310.
160. Ueda H, Manda T, Matsumoto S et al (1994b) FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968 III. Antitumor activities on experimental tumors in mice. J Antibiot 47:315-324.
161. Uekia M, Teruya T, Nie L, Usamib R, Yoshida M, Osada H (2001) New trichostatin derivative, trichostatin RK, from Streptomyces sp. RK98-A74. J Antibiot 54:1093-1095.
162. Umehara K, Nakahara K, Kiyoto S et al (1983) Studies on WF-3161, a new antitumor antibiotic. J Antibiot 36:478-483.
163. Vannini A, Volpari C, Filocamo G et al (2004) Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci U S A 101:15064-15069.
164. Voigt W (2005) Sulforhodamine B assay and chemosensitivity. Methods Mol Med 110:39-48.
165. Wang Y, Tsay Y, Chin-Ming Tan B, Lo W, Lee S (2003) Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. J Biol Chem 278:25568-25576.
166. Wegener D, Wirsching F, Riester D, Schwienhorst A (2003) A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem Biol 10:61-68.
167. Whitehurst AW, Bodemann BO, Cardenas J et al (2007) Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446:815-819.
168. Wilson AJ, Byun DS, Popova N et al (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281:13548-13558.
169. Witt O, Deubzer HE, Oehme I (2009) HDAC family: what are the cancer relevant targets? Cancer Lett 277:8-21.
170. Wood JG, Rogina B, Lavu S et al (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430:686-689.
171. Xiao B, Jing C, Wilson JR et al (2003) Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature 421:652-656.
172. Xiao JJ, Huang Y, Dai Z et al (2005) Chemoresistance to depsipeptide FK228 [(E)-(1 S, 4 S, 10 S, 21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther 314:467-475.
173. Yamaguchi H, Woods NT, Piluso LG et al (2009) p53 acetylation is crucial for its transcriptionindependent proapoptotic functions. J Biol Chem 284:11171-11183.
174. Yang M, Culhane JC, Szewczuk LM et al (2007) Structural basis of histone demethylation by LSD1 revealed by suicide inactivation. Nat Struct Mol Biol 14:535-539.
175. Yang Y, Rao R, Shen J et al (2008) Role of acetylation and extracellular location of heat shock protein 90A in tumor cell invasion. Cancer Res 68:4833-4842.
176. Ying Y, Taori K, Kim H, Hong J, Luesch H (2008) Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc 130:8455-8459.
177. Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174-17179.
178. Young CW, Fanucchi MP, Walsh TD et al (1988) Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals. Cancer Res 48:7304-7309.
179. Yuan Z, Guan Y, Chatterjee D, Chin YE (2005) Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307:269-273.
180. Zarse K, Schmeisser S, Birringer M, Falk E, Schmoll D, Ristow M (2010) Differential effects of resveratrol and SRT1720 on lifespan of adult Caenorhabditis elegans. Horm Metab Res 42:837-839.
181. Zhang X, Cheng X (2003) Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. Structure 11:509-520.
182. Zhang X, Yang Z, Khan SI et al (2003a) Structural basis for the product specificity of histone lysine methyltransferases. Mol Cell 12:177-185.
183. Zhang Y, Li N, Caron C et al (2003b) HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 22:1168-1179.
184. Zhao Y, Lu S, Wu L et al (2006) Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21Waf1/Cip1. Mol Cell Biol 26:2782-2790.
185. Zhao S, Xu W, Wenqing J et al (2010) Regulation of cellular metabolism by protein lysine acetylation. Science 327:1000-1004.